BARD1 and breast carcinoma: Tumor-bearing mice were randomized and treated five days/week with either vehicle (referred to as “Veh” in the figures) or the PARPi talazoparib (referred to as “Tal” in the figures), an FDA-approved PARPi in human breast cancer, at a dose of 0.3 mg/kg body weight/day starting at either 14 days (Brca1-def) or 7 days (Bard1-def) post tumor-cell injection (see schematic in Fig. 1A,D).